INTRODUCTION

Hantavirus (Bunyaviridas,
The pathogenesis of HCPS, like that of many other viral hemorrhagic fevers, is little understood. The core abnormalities that define the pathogenesis generally include capillary leak syndrome that selectively involves the pulmonary bed, noncardiogenic pulmonary edema, thrombocytopenia, hypotension and/or cardiogenic shock. The long incubation period for illness, the generally well-advanced adaptive immune response at the time of onset of disease, and the apparent absence of direct lytic damage to vascular endothelium are among the findings that have been taken as evidence that HCPS pathogenesis is largely immune-mediated [3] [4] [5] [6] . However, some workers have begun to challenge this assessment, citing, for example, the ability of hantaviruses to directly establish potentially maladaptive signaling cascades and to cause directly pathogenic effects on endothelial cells, such as impairing their ability to migrate across substrata, at least in vitro [7] [8] [9] [10] [11] .
A key question that would help to establish a potential role for antiviral intervention in therapy is whether viral load during acute illness can be associated with adverse clinical outcome. A study that attempted to determine whether such an association existed was able to correlate high viral RNA titers only with surrogate markers of severity such as the severity of thrombocytopenia, but its power may have been too limited to establish whether viral RNA titer is directly correlated with adverse clinical outcome [4] . Another study that used a blinded study design showed that high levels of neutralizing antibodies was associated with a favorable clinical progression in patients with HCPS [12] .
The advent of sensitive real time RT-PCR assays for SNV RNA quantitation prompted us to reinvestigate the question of whether SNV RNA titer can be associated with adverse clinical outcome in patients in the acute stages of SNV infection [13, 14] .
Using a larger panel of plasma samples than has previously been available, we have determined that there does appear to be an association between the titer of SNV RNA and disease severity in patients in the early stages of HCPS, and that viral RNA is of low abundance or absent in tracheal aspirates and urine respectively. Spiking controls. To ensure the efficiency of our RNA extraction and nested RT-PCR processes, we spiked negative plasma and negative urine samples with supernatants of infected Vero E6 cells containing 2, 10, 100, or 1,000 copies of total S segment RNA.
MATERIALS AND METHODS
Study
For experimental "spiking" of plasma or urine samples, we used particles from SNV strain SN77734 that were propagated in Vero E6 cells to most closely mimic the form of viral particles that we expected could be present in the samples from infected patients (R.
Xiao, unpublished data). Known amounts of viral RNA-equivalents, as determined by
TaqMan RT-PCR were added into negative-control plasma or urine samples in a volume of 200 µl before we prepared RNA. We suspended the resulting RNA into a volume of 50 µl. Total RNA derived from 40 µl of the virally-spiked samples were loaded in each RT-PCR reaction as described above.
Statistical analysis. Number of RNA copies was summarized with means and standard deviations for triplicate assays. Viral RNA copies were compared between patients with mild-moderate and severe diseases using the exact version of the Wilcoxon rank sum test. P-values of < 0.05 were considered statistically significant. (Table 1 ).
RESULTS
All six patients exhibited RNA viremia (defined here as the presence of viral RNA, not infectious virus) in plasma samples. We found that viral RNA was present in plasma samples from all six patients during at least the first four days of hospitalization.
Patient VI, who was in the intensive care unit for thirteen days and was the only patient monitored after d5, was positive for SNV RNA from d0 to d7 in her plasma samples, with no detectable viral RNA in her plasma samples on subsequent days (Table 1) .
A 5-ml sample of tracheal aspirate was taken daily through the endotracheal tube from the patients who required mechanical ventilation during hospitalization. Tracheal aspirate samples from the four patients on mechanical ventilation were screened for viral RNA by nested RT-PCR (Table 1) . We were able to screen nine tracheal aspirate samples from d0 to d10 while patient VI was in the intensive care unit. We found that her tracheal aspirate samples were positive for viral RNA from d0 to d4, and there was no detectable viral RNA in her tracheal aspirate starting at d5 (Table 1) . We also examined three tracheal aspirate samples collected within the first 48 hours after admission from another three patients whose plasma samples exhibited detectable viral RNA. Of the three samples examined by nested RT-PCR, all three tracheal aspirates displayed viral RNA (data not shown).
To examine the sensitivity of our nested RT-PCR, we spiked human plasma and urine samples from healthy individuals with known quantities of cell-free virus particles.
With nested RT-PCR, our sensitivity thresholds were no more than 2 copies of viral RNA from healthy human plasma and urine samples ( Figure 1 ).
A panel of 38 urine samples from the six patients was examined for viral RNA by nested PCR. We found that there was no detectable viral RNA present in any of the urine samples. Attempts to produce amplification products from centrifuged urinary sediment were also unsuccessful (N=3).
Quantitative RT-PCR. To examine the changes of viral RNA load as a function of time in a patient during the acute phase of disease, we quantified viral RNA in plasma and tracheal aspirate samples of the six patients with HCPS throughout the entire time course (day zero of hospitalization to at least day 5 in the intensive care unit). Our quantitative RT-PCR system was less sensitive than nested RT-PCR, but allowed us to track viral RNA load at levels of ≥ 5,000 copies per ml.
All six patients had viral RNA in plasma, with peak titers ranging from 1.5 x 10 5 to 1.8 x 10 6 per ml, in all cases occurring within the first three days of hospitalization (Table 1 ) (Figure 2 ). Four patients had viral RNA in tracheal aspirates with titers up to 8
x 10 4 per ml (Table 1) . Peak vRNA titers for tracheal aspirates were also found in the first three days of admission ( Figure 2 ). Starting on day 2 or day 3 after hospital admission, the number of viral RNA copies began to decrease in both plasma and tracheal aspirate samples ( Figure 2) . We found that the number of viral RNA copies in tracheal aspirate never exceeded the level of viral RNA load in plasma sample from a patient at any time point examined, nor were there any instances in which viral RNA in tracheal aspirate was detectable and undetectable in plasma (Figure 2 ).
We also screened three tracheal aspirates taken within the first 48 hours after admission from another three patients with HCPS and found that the number of viral RNA copies in each of these specimens did not exceed the titer of 2 x 10 4 per ml (data not shown).
Viral load in severe and mild-moderate cases. To ascertain whether there is an association between the viral RNA load and the disease severity in patients with HCPS, we studied 27 patients during the acute phase of the disease, including 17 patients with severe disease and 10 patients with mild-moderate disease. Table 2 Of those whose sample had levels of S segment negative-strand RNA above the cutoff for assay sensitivity of 5000 copies/ml, those with mild-moderate and severe disease had an average of 27,800 and 438,545 copies/ml, respectively. Looking at all patients, we observed that the median number of viral RNA copies was higher for patients with severe disease as compared to those with mild-moderate disease (p < 0.005).
DISCUSSION
Our study demonstrates a statistically significant association (P<0.005) between the titer of SNV RNA and the disease severity in patients in the early stages of HCPS.
This finding is in contrast to a previous study by Terajima et al in 1999 where it was not possible to show an association between viremia and disease severity, although it was possible to show an association between load and surrogate lab markers for severity [4] .
In this study, we studied plasma viral RNA load by quantitative TaqMan RT-PCR, which is a relatively robust and sensitive technique that has been used extensively in rodent here, and there were other important methodologic differences [5] .
Our findings on the association between viral load in plasma and disease severity indicate that those patients with high viral loads on admission are more likely to have a severe course of disease. Previously we showed that a high-titer neutralizing antibody response early in the course of hospitalization may be a predictor of a non-fatal outcome in SNV infection [12] . It is possible that variations in viral load are related to variations among titers of neutralizing antibody, but additional studies will be needed to further clarify this relationship. The premise that the pathogenesis of HCPS is immune-mediated is widely cited by workers in the field [2] . However, the present study suggests that ongoing in vivo replication of SNV might still be an important determinant of disease Hantaviruses have been very difficult to isolate from human sources despite many past attempts to do so. Using six plasma/tracheal aspirate specimen collected from HCPS patients during the first day of hospitalization, we applied 1-ml of sample, either neat or diluted at 1:5 in media, onto subconfluent Vero E6 cells and blind-passaged the cells for 4-6 wk, after which we screened the culture supernatants for the presence of viral RNA.
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